<DOC>
	<DOCNO>NCT01377103</DOCNO>
	<brief_summary>The purpose study evaluate whether benefit topical testosterone symptom function male HF patient , effect rehospitalization rate quality life .</brief_summary>
	<brief_title>Testosterone Therapy Heart Failure</brief_title>
	<detailed_description>Recent evidence start emerge regard benefit testosterone heart failure ( HF ) population . Firstly , testosterone directly augment vascular resistance cause vasodilation peripheral vessel decrease afterload improve cardiac output . In addition , testosterone cause coronary artery vasodilation improve cardiac ischemic threshold base subjective objective measure . Clinically , several study point potential benefit patient HF derive testosterone therapy . Measures cardiopulmonary function test , six minute walk test , incremental shuttle walk test baroreflex sensitivity , prognostic implication patient HF , show improvement addition testosterone therapy traditional-medical management . In addition objective measurement , mood , NYHA functional class muscle strength improve treatment testosterone supplementation . While past study use functional prognostic measure outcomes , issue common patient HF , sexual dysfunction repeat hospitalization , potential improvement testosterone therapy The majority study perform past utilized intramuscular transdermal patch delivery system testosterone mean supplementation . These method inherent issue mean treatment patient often time mean receive intramuscular injection patch high level skin reaction make compliance difficult . Topical administration testosterone gel may prove efficacious method testosterone supplementation lower side effect profile adequate absorption . It use success general public treatment hypogonadal symptom , study HF population . With emergence study show promise benefit testosterone supplementation HF population , ease topical administration population would provide benefit million suffer HF . The investigator study aim find benefit topical testosterone symptom function HF patient , effect rehospitalization rate quality life .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>male NYHA class IIIV Heart Failure age &gt; 35 &lt; 80 total testosterone level &lt; 5 ng/ml elevated prostate specific antigen elevate total free testosterone level prostate cancer evidence symptomatic prostatism untreated prolactinemia history breast cancer</criteria>
	<gender>Male</gender>
	<minimum_age>36 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>heart failure</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone</keyword>
</DOC>